| Dr Jerome L Kuhnlein, MD | |
|
3950 Hollywood Rd, Suite 210, Saint Joseph, MI 49085-9159 | |
| (269) 985-1000 | |
| (269) 983-1627 |
| Full Name | Dr Jerome L Kuhnlein |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 40 Years |
| Location | 3950 Hollywood Rd, Saint Joseph, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619937315 | NPI | - | NPPES |
| 4176450 | Medicaid | MI | |
| 383513843 | Other | MI | TAX ID |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lakeland Hospital, St Joseph | St joseph, MI | Hospital |
| Lakeland Hospital Watervliet | Watervliet, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lakeland Medical Practices | 1658427042 | 274 |
| Lakeland Hospitals At Niles And St Joseph Inc | 7517929037 | 91 |
News Archive
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
What do laboratory mice at the University of Michigan Medical School have in common with millions of overweight Americans? Like many of us, these mice just can't stop eating.
Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.
Statens Serum Institut and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.
› Verified 3 days ago
| Entity Name | Lakeland Hospitals At Niles And St Joseph Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134220031 PECOS PAC ID: 7517929037 Enrollment ID: O20041027001172 |
News Archive
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
What do laboratory mice at the University of Michigan Medical School have in common with millions of overweight Americans? Like many of us, these mice just can't stop eating.
Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.
Statens Serum Institut and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.
› Verified 3 days ago
| Entity Name | Lakeland Medical Practices |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538397120 PECOS PAC ID: 1658427042 Enrollment ID: O20090928000216 |
News Archive
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
What do laboratory mice at the University of Michigan Medical School have in common with millions of overweight Americans? Like many of us, these mice just can't stop eating.
Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.
Statens Serum Institut and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jerome L Kuhnlein, MD 3950 Hollywood Rd, Suite 110, Saint Joseph, MI 49085-9159 Ph: (269) 985-1000 | Dr Jerome L Kuhnlein, MD 3950 Hollywood Rd, Suite 210, Saint Joseph, MI 49085-9159 Ph: (269) 985-1000 |
News Archive
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
What do laboratory mice at the University of Michigan Medical School have in common with millions of overweight Americans? Like many of us, these mice just can't stop eating.
Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.
Statens Serum Institut and Aeras today announced the initiation of a Phase I/IIa clinical trial for a candidate tuberculosis vaccine designed to protect people, especially those latently infected with TB, from developing active TB disease.
› Verified 3 days ago
Hany S Mesiha, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-983-8300 | |
Thomas Ryan Birris, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3903 Hollywood Rd, Saint Joseph, MI 49085 Phone: 269-408-1100 | |
Kimberlee Ann Tomerlin, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3950 Hollywood Rd Ste 100, Saint Joseph, MI 49085 Phone: 269-429-8010 | |
Dr. Robert M Allen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-471-7741 Fax: 269-471-1581 | |
Michael Scott Morris, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1234 Napier Ave, Saint Joseph, MI 49085 Phone: 269-982-4862 Fax: 269-985-4523 | |
Dr. Yu-lam Christopher Chiu, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3950 Hollywood Rd, Suite 110, Saint Joseph, MI 49085 Phone: 269-985-1000 Fax: 269-983-1627 | |
Dr. Anthony P Salvagione, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 Lester Ave, Saint Joseph, MI 49085 Phone: 269-985-0029 Fax: 269-985-0040 |